Updates are available Correction dated 2025-12-08
Click to view Correction: https://doi.org/10.1007/s13402-025-01128-8
-
Authors
Pozios, Ioannis
Seel, Nina N.
Hering, Nina A.
Hartmann, Lisa
Liu, Verena
Camaj, Peter
Müller, Mario H.
Lee, Lucas D.
Bruns, Christiane J.
Kreis, Martin E.
Seeliger, Hendrik https://orcid.org/0000-0002-5937-052X
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (KFO128)
- License Information
-
More Information
Article History
Received: 8 November 2019
Revised: 1 September 2020
Accepted: 4 September 2020
First Online: 17 September 2020
Change Date: 6 December 2025
Change Type: Update
Change Details: The original version of this article was revised: Following the publication of this article it was noted that an incorrect immunostaining image for CD31-positive cells in the raloxifene-treated group was shown in panel 'e' of Figure 4. In the course of correcting this error, the entire Figure 4 has been revised, including updated immunostaining images and corresponding data for Ki67- and CD31-positive cells in both the control and raloxifene-treated groups. Following Editor approval, Figure 4, as well as sections 2.8 and 3.8 of the article, have been updated accordingly. These corrections do not affect the overall conclusions of the article.
Change Date: 8 December 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13402-025-01128-8
Compliance with ethical standards
: This article does not contain any studies involving human participants performed by any of the authors. All animal experiments were approved by the District Government of Upper Bavaria, Munich, Germany. Animal care and manipulation were in agreement with the European Union Guidelines on Animal Experiments (Directive 2010/63/EU).
: The authors disclose no potential conflicts of interest.
